Clinical trial
ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure"
NCT00051285 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT00051285 |
|---|---|
| Title | ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure" |
| Official title | ESSENTIAL Protocol No. My-021 and Protocol No. My-026, Each Titled: A Phase III, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive |
| Intervention type | Drug |
| Interventions | Enoximone, Enoximone placebo |
| Enrollment | 1,800 |
| Start date | Feb 1, 2002 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jan 9, 2003 |
| Last update posted | Jan 10, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: